Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C15H11I4NO4 |
Molecular Weight | 776.87 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O
InChI
InChIKey=XUIIKFGFIJCVMT-GFCCVEGCSA-N
InChI=1S/C15H11I4NO4/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23/h1-2,4-5,12,21H,3,20H2,(H,22,23)/t12-/m1/s1
Molecular Formula | C15H11I4NO4 |
Molecular Weight | 776.87 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.drugbank.ca/drugs/DB00509Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68003918
Sources: https://www.drugbank.ca/drugs/DB00509
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68003918
Dextrothyroxine is the dextrorotary isomer of the synthetic thyroxine. It is an antihyperlipidemic agent. The mechanism of action is not completely understood, but dextrothyroxine apparently acts in the liver to stimulate formation of low-density lipoprotein (LDL) and, to a much greater extent, to increase catabolism of LDL. This leads to increased excretion of cholesterol and bile acids via the biliary route into the feces, with a resulting reduction in serum cholesterol and LDL. Dextrothyroxine has no significant effect on high-density lipoproteins (HDL). Inherently, it will also bind to thyroid receptors and as it is a prohormone, it will bind as a substrate to iodide peroxidase.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2111462 Sources: https://www.drugbank.ca/drugs/DB00509 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CHOLOXIN Approved UseUsed to lower high cholesterol levels in the blood. Launch Date1967 |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6 day |
6 mg 1 times / day unknown, oral dose: 6 mg route of administration: Oral experiment type: UNKNOWN co-administered: |
LEVOTHYROXINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1% |
6 mg 1 times / day unknown, oral dose: 6 mg route of administration: Oral experiment type: UNKNOWN co-administered: |
LEVOTHYROXINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
8 mg 1 times / day steady, oral (max) Recommended Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: |
unhealthy, adult n = 18 Health Status: unhealthy Condition: diabetic Age Group: adult Sex: unknown Population Size: 18 Sources: |
Disc. AE: Loss of control of diabetes, Acidosis... Other AEs: Blood cholesterol decreased... AEs leading to discontinuation/dose reduction: Loss of control of diabetes (8 patients) Other AEs:Acidosis (1 patient) Hypoglycemic reaction (2 patients) Blood cholesterol decreased (18 patients) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Acidosis | 1 patient Disc. AE |
8 mg 1 times / day steady, oral (max) Recommended Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: |
unhealthy, adult n = 18 Health Status: unhealthy Condition: diabetic Age Group: adult Sex: unknown Population Size: 18 Sources: |
Blood cholesterol decreased | 18 patients | 8 mg 1 times / day steady, oral (max) Recommended Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: |
unhealthy, adult n = 18 Health Status: unhealthy Condition: diabetic Age Group: adult Sex: unknown Population Size: 18 Sources: |
Hypoglycemic reaction | 2 patients Disc. AE |
8 mg 1 times / day steady, oral (max) Recommended Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: |
unhealthy, adult n = 18 Health Status: unhealthy Condition: diabetic Age Group: adult Sex: unknown Population Size: 18 Sources: |
Loss of control of diabetes | 8 patients Disc. AE |
8 mg 1 times / day steady, oral (max) Recommended Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: |
unhealthy, adult n = 18 Health Status: unhealthy Condition: diabetic Age Group: adult Sex: unknown Population Size: 18 Sources: |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6777394
The relative binding affinities of liothyronine (L-T3), levothyroxine (L-T4), D-triiodothyronine (D-T3), and dextrothyroxine (D-T4) were measured in vitro. Solubilized nuclear receptors were prepared from rat anterior pituitaries. L-T3 had the highest binding for the nuclear receptor (taken as 100%). L-T4 and D-T3 binded to the nuclear receptor with similar affinities (11% and 13%, respectively), while the affinity of D-T4 represents only 3% that of L-T3.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:10:56 GMT 2023
by
admin
on
Fri Dec 15 15:10:56 GMT 2023
|
Record UNII |
4W9K63FION
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QC10AX01
Created by
admin on Fri Dec 15 15:10:56 GMT 2023 , Edited by admin on Fri Dec 15 15:10:56 GMT 2023
|
||
|
NCI_THESAURUS |
C1553
Created by
admin on Fri Dec 15 15:10:56 GMT 2023 , Edited by admin on Fri Dec 15 15:10:56 GMT 2023
|
||
|
WHO-ATC |
C10AX01
Created by
admin on Fri Dec 15 15:10:56 GMT 2023 , Edited by admin on Fri Dec 15 15:10:56 GMT 2023
|
||
|
LIVERTOX |
294
Created by
admin on Fri Dec 15 15:10:56 GMT 2023 , Edited by admin on Fri Dec 15 15:10:56 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C61719
Created by
admin on Fri Dec 15 15:10:56 GMT 2023 , Edited by admin on Fri Dec 15 15:10:56 GMT 2023
|
PRIMARY | |||
|
30659
Created by
admin on Fri Dec 15 15:10:56 GMT 2023 , Edited by admin on Fri Dec 15 15:10:56 GMT 2023
|
PRIMARY | |||
|
4W9K63FION
Created by
admin on Fri Dec 15 15:10:56 GMT 2023 , Edited by admin on Fri Dec 15 15:10:56 GMT 2023
|
PRIMARY | |||
|
CHEMBL559
Created by
admin on Fri Dec 15 15:10:56 GMT 2023 , Edited by admin on Fri Dec 15 15:10:56 GMT 2023
|
PRIMARY | |||
|
m10840
Created by
admin on Fri Dec 15 15:10:56 GMT 2023 , Edited by admin on Fri Dec 15 15:10:56 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB01651MIG
Created by
admin on Fri Dec 15 15:10:56 GMT 2023 , Edited by admin on Fri Dec 15 15:10:56 GMT 2023
|
PRIMARY | |||
|
3292
Created by
admin on Fri Dec 15 15:10:56 GMT 2023 , Edited by admin on Fri Dec 15 15:10:56 GMT 2023
|
PRIMARY | RxNorm | ||
|
DTXSID60199000
Created by
admin on Fri Dec 15 15:10:56 GMT 2023 , Edited by admin on Fri Dec 15 15:10:56 GMT 2023
|
PRIMARY | |||
|
846
Created by
admin on Fri Dec 15 15:10:56 GMT 2023 , Edited by admin on Fri Dec 15 15:10:56 GMT 2023
|
PRIMARY | |||
|
51-49-0
Created by
admin on Fri Dec 15 15:10:56 GMT 2023 , Edited by admin on Fri Dec 15 15:10:56 GMT 2023
|
PRIMARY | |||
|
100000087788
Created by
admin on Fri Dec 15 15:10:56 GMT 2023 , Edited by admin on Fri Dec 15 15:10:56 GMT 2023
|
PRIMARY | |||
|
6951
Created by
admin on Fri Dec 15 15:10:56 GMT 2023 , Edited by admin on Fri Dec 15 15:10:56 GMT 2023
|
PRIMARY | |||
|
8730
Created by
admin on Fri Dec 15 15:10:56 GMT 2023 , Edited by admin on Fri Dec 15 15:10:56 GMT 2023
|
PRIMARY | |||
|
200-102-7
Created by
admin on Fri Dec 15 15:10:56 GMT 2023 , Edited by admin on Fri Dec 15 15:10:56 GMT 2023
|
PRIMARY | |||
|
DB00509
Created by
admin on Fri Dec 15 15:10:56 GMT 2023 , Edited by admin on Fri Dec 15 15:10:56 GMT 2023
|
PRIMARY | |||
|
Dextrothyroxine
Created by
admin on Fri Dec 15 15:10:56 GMT 2023 , Edited by admin on Fri Dec 15 15:10:56 GMT 2023
|
PRIMARY | |||
|
D003918
Created by
admin on Fri Dec 15 15:10:56 GMT 2023 , Edited by admin on Fri Dec 15 15:10:56 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |